AR070063A1 - Uso de cannabinoides combinados con un medicamento antipsicotico y metodos de tratamiento - Google Patents
Uso de cannabinoides combinados con un medicamento antipsicotico y metodos de tratamientoInfo
- Publication number
- AR070063A1 AR070063A1 ARP080105764A ARP080105764A AR070063A1 AR 070063 A1 AR070063 A1 AR 070063A1 AR P080105764 A ARP080105764 A AR P080105764A AR P080105764 A ARP080105764 A AR P080105764A AR 070063 A1 AR070063 A1 AR 070063A1
- Authority
- AR
- Argentina
- Prior art keywords
- antipsychotic
- acid
- phytocannabinoids
- medicinal
- treatment methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Reivindicacion 1: El uso de uno o más fitocannabinoides con uno o más medicamentos antipsicoticos en la elaboracion de una formulacion farmacéutica para su empleo en la prevencion o el tratamiento de la psicosis o de un trastorno psicotico, caracterizado porque uno o más de los fitocannabinoides se administran en forma separada, en secuencias o de manera simultánea a uno o más medicamentos antipsicoticos. Reivindicacion 2: El uso segun la reivindicacion 1, caracterizado porque el o los fitocannabinoides se toman del grupo constituido por: cannabidiol (CBD), ácido cannabidiolico (CBDA), tetrahidrocannabidivarina (THCV), ácido tetrahidrocannabidivarinina (THCVA), cannabicromeno (CBC), ácido cannabicroménico (CBCA), cannabigerol (CBG) y ácido cannabigerolico (CBGA). Reivindicacion 11: El uso segun cualquiera de las reivindicaciones precedentes, caracterizado porque el medicamento antipsicotico atípico se selecciona del grupo formado por: aripiprazol, risperidona, paliperidona, ziprasidona, olanzapina, quetiapina, clozapina, sulpirida, amisulprida, iloperidona, cariprazina, asenapina.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0800390A GB2456183A (en) | 2008-01-04 | 2008-01-04 | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
Publications (1)
Publication Number | Publication Date |
---|---|
AR070063A1 true AR070063A1 (es) | 2010-03-10 |
Family
ID=39144704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080105764A AR070063A1 (es) | 2008-01-04 | 2008-12-29 | Uso de cannabinoides combinados con un medicamento antipsicotico y metodos de tratamiento |
Country Status (25)
Country | Link |
---|---|
US (1) | US9017737B2 (es) |
EP (3) | EP2609928B1 (es) |
JP (1) | JP5409650B2 (es) |
KR (1) | KR101631518B1 (es) |
CN (1) | CN101939017B (es) |
AR (1) | AR070063A1 (es) |
AU (1) | AU2008346285B2 (es) |
BR (1) | BRPI0821461A8 (es) |
CA (1) | CA2708921C (es) |
CL (1) | CL2008003902A1 (es) |
CO (1) | CO6290695A2 (es) |
ES (3) | ES2751117T3 (es) |
GB (3) | GB2456183A (es) |
HU (2) | HUE046780T2 (es) |
IL (1) | IL206784A0 (es) |
MX (1) | MX2010007073A (es) |
NZ (1) | NZ586648A (es) |
PE (2) | PE20141249A1 (es) |
PL (2) | PL2609928T3 (es) |
PT (2) | PT2609928T (es) |
RU (1) | RU2503448C2 (es) |
TW (2) | TWI519299B (es) |
UA (1) | UA103472C2 (es) |
WO (1) | WO2009087351A1 (es) |
ZA (1) | ZA201005443B (es) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
GB2377218A (en) * | 2001-05-04 | 2003-01-08 | Gw Pharmaceuticals Ltd | Process and apparatus for extraction of active substances and enriched extracts from natural products |
AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
GB0425248D0 (en) | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
KR20070089151A (ko) | 2004-11-16 | 2007-08-30 | 지더블유 파마 리미티드 | 카나비노이드의 새로운 용도 |
GB2459637B (en) * | 2008-01-21 | 2012-06-06 | Gw Pharma Ltd | New use for cannabinoids |
GB2471523A (en) | 2009-07-03 | 2011-01-05 | Gw Pharma Ltd | Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy |
GB2478595B (en) * | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
US8772349B2 (en) * | 2010-03-26 | 2014-07-08 | Vivacell Biotechnology Espana, S.L. | Cannabinoid quinone derivatives |
TWI583374B (zh) | 2010-03-30 | 2017-05-21 | Gw伐瑪有限公司 | 使用植物大麻素次大麻二酚(cbdv)來治療癲癇之用途 |
US8445034B1 (en) | 2010-11-02 | 2013-05-21 | Albert L Coles, Jr. | Systems and methods for producing organic cannabis tincture |
US9775379B2 (en) | 2010-12-22 | 2017-10-03 | Syqe Medical Ltd. | Method and system for drug delivery |
GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
AU2014302410B2 (en) * | 2013-06-26 | 2019-06-13 | Amgen Inc. | CB1 receptor antigen-binding proteins and uses thereof |
CN105848646B (zh) | 2013-10-29 | 2019-10-22 | 艾克制药有限公司 | 包含大麻二酚的压制片剂、其制造方法以及此类片剂在口服治疗精神病症或焦虑症中的用途 |
AU2014340710B2 (en) | 2013-10-29 | 2019-08-22 | Echo Pharmaceuticals B.V. | Compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment |
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
GB2527599A (en) | 2014-06-27 | 2015-12-30 | Gw Pharma Ltd | Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy |
DK3160558T3 (da) | 2014-06-30 | 2020-04-27 | Syqe Medical Ltd | Strømningsregulerende indåndingsanordning |
WO2016001922A1 (en) | 2014-06-30 | 2016-01-07 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
EP3160565B1 (en) | 2014-06-30 | 2021-08-18 | Syqe Medical Ltd. | Devices and systems for pulmonary delivery of active agents |
US10099020B2 (en) | 2014-06-30 | 2018-10-16 | Syqe Medical Ltd. | Drug dose cartridge for an inhaler device |
CN106573118B (zh) * | 2014-06-30 | 2020-07-03 | Syqe医药有限公司 | 用于活性剂的肺部递送的方法、装置及系统 |
US11298477B2 (en) | 2014-06-30 | 2022-04-12 | Syqe Medical Ltd. | Methods, devices and systems for pulmonary delivery of active agents |
EP3954417A1 (en) | 2014-06-30 | 2022-02-16 | Syqe Medical Ltd. | Method and device for vaporization and inhalation of isolated substances |
GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2531281A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
US9539295B2 (en) | 2014-12-05 | 2017-01-10 | Bradley Michael Bohus | Cannabidiol (CBD) enriched alcohol |
GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
US9585867B2 (en) | 2015-08-06 | 2017-03-07 | Charles Everett Ankner | Cannabinod formulation for the sedation of a human or animal |
GB2541191A (en) | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
GB2542155B (en) | 2015-09-09 | 2018-08-01 | Gw Pharma Ltd | Use of cannabidiol in the treatment of mental disorders |
KR20180095674A (ko) | 2015-12-22 | 2018-08-27 | 조게닉스 인터내셔널 리미티드 | 대사 저항성 펜플루라민 유사체 및 그 사용 방법 |
CN113499330A (zh) | 2015-12-22 | 2021-10-15 | 周格尼克斯国际有限公司 | 芬氟拉明组合物及其制备方法 |
AU2017204945B2 (en) | 2016-01-06 | 2022-11-10 | Syqe Medical Ltd. | Low dose therapeutic treatment |
GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
US10499584B2 (en) | 2016-05-27 | 2019-12-10 | New West Genetics | Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles |
EP3478307A4 (en) | 2016-06-29 | 2020-02-26 | Cannscience Innovations Inc. | DECARBOXYLATED CANNABIS RESINS, USES AND METHODS OF MAKING |
GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
US20180021326A1 (en) | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
US20210069170A1 (en) | 2016-07-23 | 2021-03-11 | Paul Edward Stamets | Tryptamine compositions for enhancing neurite outgrowth |
US11701348B1 (en) | 2016-07-23 | 2023-07-18 | Turtle Bear Holdings, Llc | Psilocybin compositions |
AU2017315273B2 (en) | 2016-08-24 | 2021-04-29 | Zogenix International Limited | Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same |
GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
US10835501B2 (en) | 2016-10-01 | 2020-11-17 | Indication Bioscience Llc | Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof |
CN108078984B (zh) * | 2016-11-23 | 2020-11-20 | 汉义生物科技(北京)有限公司 | 5-羟色胺和去甲肾上腺素再摄取抑制剂与大麻二酚的组合物及其应用 |
CN108143726B (zh) * | 2016-12-02 | 2020-05-08 | 汉义生物科技(北京)有限公司 | 大麻二酚与5-ht2a受体拮抗剂及5-ht再摄取抑制剂的药物组合物及其用途 |
GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
PL3338768T3 (pl) | 2016-12-20 | 2020-05-18 | Lts Lohmann Therapie-Systeme Ag | Transdermalny system terapeutyczny zawierający asenapinę |
AU2017384392B2 (en) | 2016-12-20 | 2023-05-25 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
US11974984B2 (en) | 2017-02-09 | 2024-05-07 | Caamtech, Inc. | Compositions and methods comprising a combination of serotonergic drugs |
US20190142851A1 (en) * | 2017-11-16 | 2019-05-16 | CaaMTech, LLC | Compositions comprising a psilocybin derivative and a cannabinoid |
CA3052974A1 (en) | 2017-02-09 | 2018-08-16 | CaaMTech, LLC | Compositions and methods comprising a psilocybin derivative |
US20210346346A1 (en) | 2017-02-09 | 2021-11-11 | Caamtech, Inc. | Compositions comprising a serotonergic tryptamine compound |
GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
JP2020525545A (ja) | 2017-06-26 | 2020-08-27 | エルテーエス ローマン テラピー−ジステーメ アーゲー | アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム |
CN107469087A (zh) * | 2017-09-10 | 2017-12-15 | 孙永丽 | 用于治疗精神病的制剂 |
US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
CA3084953A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
MX2020005517A (es) | 2017-12-05 | 2020-11-09 | Sunovion Pharmaceuticals Inc | Formas cristalinas y metodos de produccion de las mismas. |
GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
EP3755318B1 (en) * | 2018-02-20 | 2022-08-24 | MyMD Pharmaceuticals, Inc. | Genetically modified cannabis sativa plants and modified cannabinoid compounds for treatment of substance addiction and other disorders |
EP3790537A1 (en) | 2018-05-11 | 2021-03-17 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
MX2020014286A (es) | 2018-06-20 | 2021-03-25 | Lts Lohmann Therapie Systeme Ag | Sistema terapeutico transdermico que contiene asenapina. |
WO2020188569A1 (en) * | 2019-03-20 | 2020-09-24 | Bol Pharma Ltd. | Methods and compositions for preventing or treating weight gain caused by psychiatric drugs |
SG11202113266YA (en) | 2019-06-04 | 2021-12-30 | Sunovion Pharmaceuticals Inc | Modified release formulations and uses thereof |
CA3158059A1 (en) | 2019-11-19 | 2021-05-27 | Paul Edward Stamets | Tryptamine compositions for enhancing neurite outgrowth |
GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
CA3187303A1 (en) | 2020-07-28 | 2022-02-03 | Impello Biosciences, Inc. | Methods and compositions for altering secondary metabolites in plants |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
US11337934B1 (en) | 2021-04-08 | 2022-05-24 | Lanny Leo Johnson | Compositions including a cannabinoid and protocatechuic acid |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5006528A (en) * | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
IL136839A (en) * | 2000-06-16 | 2006-12-10 | Yissum Res Dev Co | Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same |
US7053092B2 (en) * | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
AR032641A1 (es) | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
DE60202270T2 (de) * | 2001-03-22 | 2005-05-19 | Solvay Pharmaceuticals B.V. | 4,5-dihydro-1h-pyrazolderivate mit cb1-antagonistischer wirkung |
MY129350A (en) * | 2001-04-25 | 2007-03-30 | Bristol Myers Squibb Co | Aripiprazole oral solution |
AU2003226149A1 (en) * | 2002-04-05 | 2003-10-27 | Merck & Co., Inc. | Substituted aryl amides |
DE10226494A1 (de) * | 2002-06-14 | 2004-01-08 | Lts Lohmann Therapie-Systeme Ag | Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen |
GB2392093B (en) * | 2002-08-14 | 2006-03-08 | Gw Pharma Ltd | Pharmaceutical formulations |
GB0222077D0 (en) | 2002-09-23 | 2002-10-30 | Gw Pharma Ltd | Methods of preparing cannabinoids from plant material |
DK1575590T3 (da) | 2002-12-27 | 2008-02-11 | Otsuka Pharma Co Ltd | Carbostyrilderivater og serotoningenoptagelsesinhibitorer til behandling af sindsstemningslidelser |
CN102172402A (zh) * | 2003-05-23 | 2011-09-07 | 大塚制药株式会社 | 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂 |
WO2005000830A1 (en) * | 2003-06-24 | 2005-01-06 | Gw Pharma Limited | Pharmaceutical compositions comprising cabbinochreme type compounds |
CA2537535A1 (en) * | 2003-09-02 | 2005-03-10 | Solvay Pharmaceuticals Gmbh | Novel medical use of selective cb1-receptor antagonists |
AU2004273865A1 (en) * | 2003-09-18 | 2005-03-31 | Merck & Co., Inc. | Substituted sulfonamides |
CA2550435A1 (en) * | 2003-12-19 | 2005-07-14 | Bristol-Myers Squibb Company | Azabicyclic heterocycles as cannabinoid receptor modulators |
WO2006017892A1 (en) * | 2004-08-16 | 2006-02-23 | Northern Sydney And Central Coast Area Health Service | Methods for improving cognitive functioning |
GB0425248D0 (en) * | 2004-11-16 | 2004-12-15 | Gw Pharma Ltd | New use for cannabinoid |
KR20070089151A (ko) * | 2004-11-16 | 2007-08-30 | 지더블유 파마 리미티드 | 카나비노이드의 새로운 용도 |
FR2882931B1 (fr) * | 2005-03-14 | 2007-05-18 | Sanofi Aventis Sa | Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique |
PE20071092A1 (es) * | 2005-12-08 | 2007-12-10 | Aventis Pharma Inc | Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico |
JP2009537523A (ja) * | 2006-05-15 | 2009-10-29 | メルク エンド カムパニー インコーポレーテッド | 三級アルコールのプロドラッグ |
GB2438682A (en) * | 2006-06-01 | 2007-12-05 | Gw Pharma Ltd | New use for cannabinoids |
EP1867308B1 (en) | 2006-06-12 | 2010-10-20 | Camp Scandinavia Ab | Frame for a hyperextension brace |
US8481085B2 (en) * | 2006-06-15 | 2013-07-09 | Gw Pharma Limited | Pharmaceutical compositions comprising cannabigerol |
GB2439393B (en) * | 2006-06-23 | 2011-05-11 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
WO2008133884A2 (en) | 2007-04-23 | 2008-11-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
US8889076B2 (en) * | 2008-12-29 | 2014-11-18 | Uop Llc | Fluid catalytic cracking system and process |
-
2008
- 2008-01-04 GB GB0800390A patent/GB2456183A/en not_active Withdrawn
- 2008-12-17 PT PT131526006T patent/PT2609928T/pt unknown
- 2008-12-17 BR BRPI0821461A patent/BRPI0821461A8/pt not_active IP Right Cessation
- 2008-12-17 HU HUE16167562A patent/HUE046780T2/hu unknown
- 2008-12-17 EP EP13152600.6A patent/EP2609928B1/en active Active
- 2008-12-17 WO PCT/GB2008/004217 patent/WO2009087351A1/en active Application Filing
- 2008-12-17 ES ES13152600T patent/ES2751117T3/es active Active
- 2008-12-17 NZ NZ586648A patent/NZ586648A/xx unknown
- 2008-12-17 PL PL13152600T patent/PL2609928T3/pl unknown
- 2008-12-17 MX MX2010007073A patent/MX2010007073A/es active IP Right Grant
- 2008-12-17 ES ES16167562T patent/ES2750728T3/es active Active
- 2008-12-17 UA UAA201009705A patent/UA103472C2/uk unknown
- 2008-12-17 GB GB1012953.4A patent/GB2468828B/en active Active
- 2008-12-17 CA CA2708921A patent/CA2708921C/en active Active
- 2008-12-17 US US12/811,393 patent/US9017737B2/en active Active
- 2008-12-17 AU AU2008346285A patent/AU2008346285B2/en active Active
- 2008-12-17 JP JP2010541094A patent/JP5409650B2/ja active Active
- 2008-12-17 RU RU2010132649/15A patent/RU2503448C2/ru active
- 2008-12-17 PT PT161675624T patent/PT3095452T/pt unknown
- 2008-12-17 KR KR1020107017111A patent/KR101631518B1/ko active IP Right Grant
- 2008-12-17 EP EP08869534.1A patent/EP2249848B1/en active Active
- 2008-12-17 EP EP16167562.4A patent/EP3095452B1/en active Active
- 2008-12-17 CN CN200880125822.5A patent/CN101939017B/zh active Active
- 2008-12-17 HU HUE13152600A patent/HUE047214T2/hu unknown
- 2008-12-17 ES ES08869534.1T patent/ES2574155T3/es active Active
- 2008-12-17 PL PL16167562T patent/PL3095452T3/pl unknown
- 2008-12-24 CL CL2008003902A patent/CL2008003902A1/es unknown
- 2008-12-29 AR ARP080105764A patent/AR070063A1/es unknown
- 2008-12-31 TW TW097151656A patent/TWI519299B/zh active
- 2008-12-31 TW TW103121762A patent/TW201436791A/zh unknown
-
2009
- 2009-01-05 PE PE2014000565A patent/PE20141249A1/es not_active Application Discontinuation
- 2009-01-05 PE PE2009000002A patent/PE20091361A1/es not_active Application Discontinuation
-
2010
- 2010-07-04 IL IL206784A patent/IL206784A0/en active IP Right Grant
- 2010-07-29 ZA ZA2010/05443A patent/ZA201005443B/en unknown
- 2010-08-04 CO CO10095174A patent/CO6290695A2/es not_active Application Discontinuation
-
2012
- 2012-09-21 GB GBGB1216932.2A patent/GB201216932D0/en not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR070063A1 (es) | Uso de cannabinoides combinados con un medicamento antipsicotico y metodos de tratamiento | |
ES2524320T3 (es) | Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo | |
JP2011508765A5 (es) | ||
SV2010003451A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
CO6251364A2 (es) | Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k | |
AR073123A1 (es) | Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica | |
BR112017006957A2 (pt) | formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína | |
CL2011001536A1 (es) | Compuestos derivados de pirimidin-2-il-1h-indol, inhibidores de la proteina quinasa atr; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del cancer. | |
CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
ECSP099451A (es) | Compuestos de urea policíclicos antibacterianos | |
ECSP10010419A (es) | Derivados heterocíclicos de urea y métodos de uso de los mismos-211 | |
UY30559A1 (es) | Derivados de morfolino pirimidina, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
BR112013004440A2 (pt) | método para administração parenteral de uma composição, composição farmacêutica para administração parenteral, kit e sistema farmacêutico para administração parenteral | |
CL2012003350A1 (es) | Composicion farmaceutica inyectable de liberacion controlada que comprende risperidona, un copolimero de acido lactico y glicolico, un disolvente miscible en agua, una viscosidad y una relacion de masas de disolvente/farmaco y de farmaco/polimero especificas; kit farmaceutico; y uso para tratar esquizofrenia o trastornos bipolares. | |
BRPI0912842A8 (pt) | composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina | |
UY32315A (es) | Compuestos de piperidina y usos de los mismo-596 | |
BR112013017750A2 (pt) | nanocápsulas com envoltório polimérico | |
CO6710926A2 (es) | Compuestos de n-heteroarilo | |
AR060786A1 (es) | Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina | |
CO6640218A2 (es) | Heterociclilbencillporazoles sustituidos y uso de los mismos | |
ECSP10010664A (es) | Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas | |
UY32856A (es) | Derivados heterocíclicos de urea y métodos de uso de los mismos | |
CO6361995A2 (es) | Derivados de isoquinolinona como antagonistas de nk3 | |
UY32694A (es) | Derivados heterocíclicos de urea y métodos de uso de los mismos | |
Zhou et al. | Morusin inhibits the growth of human colorectal cancer HCT116‑derived sphere‑forming cells via the inactivation of Akt pathway |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |